passionate drug hunter, avid cyclist, world traveler
Boston, MA
Joined November 2016
- Tweets291
- Following271
- Followers384
- Likes373
Markus Warmuth retweeted
Recent disappointing study results have sparked debate about the role of inflammation in CVD.
Our SVP and Head of Translational Biology Manav Korpal explains why it remains a valid target and why we believe the opportunity lies upstream with NEK7/NLRP3: lnkd.in/p/gse_tT2t
Markus Warmuth retweeted
Today, we report financial results and business highlights for the second quarter 2026.
CEO @markus_warmuth shares his perspective on our second quarter performance, recent milestones, and the continued momentum across our pipeline.
Read more: bit.ly/4hcjyj0
Markus Warmuth retweeted
At this year’s 2025 Stifel I&I Forum, our CEO, @markus_warmuth, will participate in a fireside chat and provide an overview of our I&I pipeline progress. Learn more: bit.ly/47YaolJ
Markus Warmuth retweeted
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐞𝐧𝐞𝐬: BiotechTV visited @MonteRosaTx in Boston, MA yesterday and learned about the work they are doing on molecular glue degraders. Scientist Katherine Jones showed us some of the equipment that makes it happen.
40yrs LiveAid! 40 years ago at 6.41pm Queen came on stage for their legendary performance! When we had to name our @MonteRosaTx product engine we wanted it to represent greatness and doing the impossible. So we picked QuEEN! Best choice ever! Aye-Oh!
Markus Warmuth retweeted
ICYMI: Last week, we published discoveries in a @ScienceMagazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs & our QuEEN™ discovery engine. bit.ly/4kvoGwH
Over the last 6 years we @MonteRosaTx have pushed the limits on molecular glue degrader design. The term MGD didn’t even exist 6 years ago! Very proud of the team and exited about what the technology holds! Go QuEEN! Aye-Oh!
New research in Science greatly expands the potential target scope of molecular glues and should stimulate the development of new small molecules that can selectively target therapeutically relevant proteins for degradation.
Learn more in this week's issue: scim.ag/4lauo8j
ALT This illustration shows the interface of the kinase NEK7 (light blue) and the E3 ubiquitin ligase substrate receptor cereblon (teal). The interaction is facilitated by the small molecule MRT-3486 (orange).
Markus Warmuth retweeted
2024 was a transformative year for Monte Rosa. We’re thrilled with the progress we’ve made and excited to announce our strategic priorities, goals, and milestones for 2025. Read more: bit.ly/4gQ4W5O
Markus Warmuth retweeted
Today, we announced that our CEO, Markus Warmuth, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 5:15 p.m. PST. We look forward to seeing you all in San Francisco! #JPM2025 bit.ly/41W5mTE
Congrats to our CDK2 team @MonteRosaTx. Beautiful work! Go QuEEN!
We’re presenting preclinical data at @SABCSSanAntonio on the potential of our highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader.
Learn more: bit.ly/4f8gpvL
holiday season way of dealing with post game parking garage backup! Go FCB! @FCBayern
Markus Warmuth retweeted
Excellent explainer from @JuliaBauman2 on our paper - “Mining the Cereblon Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition” - showcasing our bold approach to tackling previously undruggable targets.
Thank you, Julia, for your insightful review!
How many proteins could be degraded by molecular glues?
New paper from the team at @MonteRosaTx suggests it's more than previously thought!
Study led by @gpetzold2 @CirauquiPablo @joccastle & others
2 great presentations to take a look at! Go QuEEN! Ay-Oh!
ICYMI: Our team was on the ground for this week’s 7th #TPD and Induced Proximity Summit.
View our presentations to learn more about Monte Rosa’s work on CDK2 and Cyclin E1 #moleculargluedegraders, as well as our programs in GSPT1 and VAV1.
bit.ly/3ChLkrJ
Markus Warmuth retweeted
Attending the 7th #TPD and Induced Proximity Summit?
Nina Ilic-Widlund, Director of Oncology Biology, shares how we’re accelerating the rational discovery and design of #moleculargluedegraders, including CDK2 and Cyclin E1 #MGDs. Join us to learn more!
bit.ly/40nWpS9
Such a pleasure to work with @FionaHMarshall and the team at @Novartis to execute this agreement. For @MonteRosaTx, this agreement underscores our belief in the potential of molecular glue degraders, and we are encouraged by the possibilities that lie ahead.
I’m happy to share that Novartis and @MonteRosaTx have announced an exclusive global development and commercialization license agreement to advance molecular glue degraders. ir.monterosatx.com/news-rele…
Proud to share the news of our agreement with @Novartis, which is anticipated to accelerate the development of MRT-6160 across multiple indications.
Congratulations to our amazing team!
Today we announced a global license agreement with @Novartis to advance VAV1-directed MGDs. This agreement is expected to accelerate clinical development of MRT-6160 and explore its therapeutic potential across multiple indications.
Learn more: bit.ly/3YDsioB
So much cool stuff happening in the space - great to see the progress and energy!
Thanks to Asher Mullard and @NatRevDrugDisc for the great article and interview with our CEO Markus Warmuth and our CSO Sharon Townson. nature.com/articles/d41573-0…
A target we really, really like @MonteRosaTx! Great review!
VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases dlvr.it/TBg66r
